Analysts at StockNews.com started coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Rating) in a note issued to investors on Wednesday. The brokerage set a “buy” rating on the stock.
Trinity Biotech Stock Down 4.2 %
Trinity Biotech stock opened at $0.92 on Wednesday. The company has a 50 day moving average of $0.95 and a 200-day moving average of $1.07. The company has a quick ratio of 1.39, a current ratio of 2.69 and a debt-to-equity ratio of 8.70. Trinity Biotech has a twelve month low of $0.80 and a twelve month high of $1.50. The stock has a market capitalization of $35.06 million, a PE ratio of -0.71 and a beta of 1.41.
Trinity Biotech (NASDAQ:TRIB – Get Rating) last announced its earnings results on Thursday, March 23rd. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.12). Trinity Biotech had a negative return on equity of 724.07% and a negative net margin of 54.84%. The company had revenue of $18.04 million during the quarter, compared to analyst estimates of $18.00 million. On average, equities research analysts anticipate that Trinity Biotech will post -0.22 EPS for the current fiscal year.
Institutional Investors Weigh In On Trinity Biotech
Trinity Biotech Company Profile
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O’Caoimh and Denis R.
- Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.